multimmune GmbH

.......... delivering innovative, clinical-stage broad-spectrum cancer theranostics


Cancer immunotherapy drugs are by far the fastest-growing segment of the oncology drugs industry.

multimmune GmbH's cancer theranostics programs have been supported by investment from a number of sources:

  • Technology Investment Fund Bayern III GmbH & Co. KG
  • S-Refit AG / Sobera Capital GmbH)
  • RAABE Verögensverwaltungs GmbH
  • SilverSky LifeSciences GmbH
  • Private investors